Sobi's Doptelet Launch In EU To Drive Transformation

UK Is First EU Market For Commercial Launch

05 Nov 2020

• By John Davis

Sobi is launching the thrombocytopenia drug Doptelet in Europe after acquiring the originator, Dova Pharmaceuticals, and expects to capture significant market share from older products while adding to its business in rare diseases, hematology, and immunology.

Swedish Orphan Biovitrum AB (Sobi) is pushing ahead with launching the thrombopoietin receptor agonist, Doptelet (avatrombopag, 20mg tablets), in the EU, part of its drive to transform into a hematology- and immunology-focused rare diseases company with an international footprint.

Doptelet is indicated in the EU for the treatment of severe thrombocytopenia in adult patients with chronic liver disease (CLD)...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

BioMarin’s Roctavian Continues to Shine In Hemophilia A Despite Commercial Woes

04 Jul 2025

• By Sushmita Panda

Roctavian shows durable bleed control and safety over five years, but high costs and access hurdles limit its commercial outlook.

Pfizer’s Hympavzi Poised For Broader Hemophilia Label

26 Jun 2025

• By Alaric DeArment

The drugmaker announced positive topline results for the drug in hemophilia A and B patients with inhibitors, on top of the existing approval for patients without inhibitors.

Early Blood Cancer Data Impresses As Incyte Plots Post-Jakafi Strategy

16 Jun 2025

• By Kevin Grogan

First results for a first-in-class mutCALR-targeted therapy in essential thrombocythemia presented at EHA point to a lucrative future for the early-stage product.

ASCO: Rusfertide Inches Toward FDA Filing With Positive 32-Week Data

01 Jun 2025

• By Alaric DeArment

Takeda/Protagonist are awaiting 52-week data to confirm the results from the VERIFY trial of the drug in polycythemia vera.

In Brief: BioVersys And Shionogi Align In Non-Tuberculous Mycobacteria R&D

02 Jul 2025

• By Joseph Haas

Deal Snapshot: Having recently raised an $89m IPO, BioVersys is partnering on and optioning rights to a preclinical NTM development program with Shionogi.